Biocytogen
Deyao Li is currently serving as the Business Development & Licensing Manager at Biocytogen since August 2025. Previously, Deyao held the position of Senior Research Scientist at Memorial Sloan Kettering Cancer Center from July 2020 to August 2025, focusing on chemical biology under the guidance of Dr. Minkui Luo. Deyao co-founded META Pharmaceuticals Inc. in June 2021 and contributed significantly by securing $15 million in funding to enhance research and development efforts until December 2024. Deyao's earlier roles include Postdoctoral Researcher in Cancer Biology at Dana-Farber Cancer Institute and Harvard Medical School, with an emphasis on research under Dr. Jun Qi, and Senior Scientist at WuXi AppTec, specializing in drug discovery for various therapeutic areas. Deyao Li holds a PhD in Organic Chemistry from the University of Chinese Academy of Sciences and a Bachelor's degree in Pharmaceutical Engineering from China Pharmaceutical University.
This person is not in any teams
This person is not in any offices
Biocytogen
2 followers
Biocytogen is a preclinical stage biotech that provides a one-stop solution for antibody discovery from target to IND application. With cutting-edge technologies, state-of-art animal facility, and world-class platforms for antibody drug discovery, Biocytogen offers animal model generation, antibody fully human-mouse (RenMab mouse), therapeutic antibody discovery and development, in vivo/in vitro preclinical studies, CMC/CDMO, and regulatory affairs support.